Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 8576 - 8600 of 9280 in total

Sapablursen

Sapablursen is a synthetic 2'-O-(2-methoxyethyl)-modified antisense oligonucleotide linked to a tri-antennary cluster of N-acetyl galactosamine (GalNAc3) sugars targeting transmembrane protease, serine 6 messenger ribonucleic acid
Investigational

IDUA-RTB

RTB-IDUA is a fusion protein of alpha-L-iduronidase (IDUA) and ricin transport subunit B (RTB).
Investigational

ST266

ST266 is an amniotic membrane-derived cellular cytokine solution.
Investigational

VGB-R04

VGB-R04 is an adeno-associated viral vector delivering human FIX Padua gene.
Investigational

AOC-1020

AOC-1020 is an antibody oligonucleotide conjugate, comprised of a human transferrin receptor 1 targeting, effector function null, humanized IgG1 antibody, a MCC maleimide linker, and a double-stranded siRNA oligonucleotide targeting DUX4.
Investigational

CTX130

CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.
Investigational

Allogeneic natural killer cells

Investigational

AVR-RD-05

AVR-RD-05 is a gene therapy comprising genetically modified autologous stem cells transduced ex vivo with a lentiviral vector encoding the human iduronate-2-sulfatase (IDS) enzyme. It is under investigation for the treatment of Hunter Syndrome (Mucopolysaccharidosis Type II, MPSII).
Investigational

OTL-203

OTL-203 is an autologous CD34+ enriched cell therapy that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene.
Investigational

MaaT013

MaaT013 is an allogeneic fecal microbiota therapy. It is being investigated for the treatment of Graft-Versus-Host Disease.
Investigational

ATIR101

ATIR101 is a haploidentical, naïve cell-enriched T-cell therapy.
Investigational

Allogeneic human pancreatic islets of Langerhans

Investigational

ssCART-19 cells

ssCART-19 cells consist of autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6).
Investigational

Epidermal Growth Factor Receptor variant III (EGFRvIII) chimeric antigen receptor T cells

Investigational

Autologous CD4+CD25hiFoxP3+regulatory T cells

Investigational

Avoplacel

Avoplacel (PLX-R18) is an allogeneic cell therapy under investigation for the treatment of acute radiation syndrome.
Investigational

Ex vivo expanded autologous human corneal epithelial cells containing stem cells

Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells) is a stem cell therapy used to treat limbal stem cell deficiencies.
Investigational

Rugonersen

Rugonersen is a locked nucleic acid antisense oligonucleotide under investigation for the treatment of Angelman Syndrome.
Investigational

Ulefnersen

Investigational

Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase

Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase is an investigational lentiviral gene therapy. It comprises autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that had been genetically modified ex vivo with EFS-ADA LV.
Investigational

RC88

RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).
Investigational

HLX-58

HLX-58 is an investigational monoclonal antibody targeted against claudin 18.2.
Investigational

SHR-A1904

SHR-A1904 is under investigation in clinical trial NCT04877717 (A Study of SHR-A1904 in Patients With Advanced Solid Cancer).
Investigational

rAAV1-CB-hAAT

rAAV1-CB-hAAT is a recombinant adeno-associated virus alpha 1-antitrypsin vector.
Investigational

BVX-001

BVX001 is a a novel, first-in-class CD33/CD7-directed antibody-drug conjugate.
Investigational
Displaying drugs 8576 - 8600 of 9280 in total